Related references
Note: Only part of the references are listed.Hepatic fibrosis: 2022 Unmet needs and a blueprint for the future
Scott L. Friedman et al.
HEPATOLOGY (2022)
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
Beth A. Davison et al.
JOURNAL OF HEPATOLOGY (2020)
Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study
Jorge Luis Poo et al.
HEPATOLOGY INTERNATIONAL (2020)
Acute Liver Failure During Pirfenidone Treatment Triggered by Co-Medication With Esomeprazole
Andreas Benesic et al.
HEPATOLOGY (2019)
Chronic hepatitis B virus infection
Wai-Kay Seto et al.
LANCET (2018)
Drug Idiosyncrasy Due To Pirfenidone Presenting as Acute Liver Failure: Case Report and Mini-Review of the Literature
Nipun Verma et al.
HEPATOLOGY COMMUNICATIONS (2018)
Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study
Yani Liu et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin et al.
LANCET (2013)
Pirfenidone In Idiopathic Pulmonary Fibrosis
Natalie J. Carter
DRUGS (2011)
Antifibrotic activities of pirfenidone in animal models
C. J. Schaefer et al.
EUROPEAN RESPIRATORY REVIEW (2011)
Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
Stephanos J. Hadziyannis et al.
GASTROENTEROLOGY (2006)
Share Paper
